Cutler Group LP Humanigen, Inc Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$0.09 - $0.2 $27 - $60	-300 Reduced 5.42%	5,239 $0
Q3 2022 Oct 25, 2022	SELL	$0.15 - $3.02 $1,620 - $32,634	-10,806 Reduced 66.11%	5,539 $0
Q2 2022 Aug 04, 2022	SELL	$1.76 - $3.33 $236,918 - $448,261	-134,613 Reduced 89.17%	16,345 $28,000
Q1 2022 Apr 14, 2022	BUY	$1.81 - $3.97 $243,674 - $534,469	134,627 Added 824.36%	150,958 $454,000
Q4 2021 Jan 18, 2022	BUY	$3.66 - $8.22 $40,721 - $91,455	11,126 Added 213.76%	16,331 $60,000
Q3 2021 Oct 26, 2021	BUY	$5.93 - $17.83 $4,115 - $12,374	694 Added 15.38%	5,205 $30,000
Q2 2021 Jul 19, 2021	SELL	$13.54 - $22.74 $39,117 - $65,695	-2,889 Reduced 39.04%	4,511 $78,000
Q1 2021 Apr 26, 2021	BUY	$12.91 - $23.83 $95,534 - $176,342	7,400 New	7,400 $141,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.